CommentaryOpen Access

The role of historical medical archives in the genealogical rebuilding of large families affected by neurodegenerative diseases

 Chiara Cupidi, Valentina Laganà, Nicoletta Smirne, Amalia Cecilia Bruni*


Starting from a proband for whom a family history of neurodegenerative disorder has been reported, clinical and genealogical methods are often used together to reconstruct the pedigree of many large families affected by hereditary diseases.
 
This approach was fundamental in the rebuilding of the N family, the kindred originated from southern Italy affected by early onset autosomal dominant Alzheimer’s disease (AD), that has given an important contribution to the discovery of Presenilin 1, the main gene responsible for AD.
 
The identification of several patients in this pedigree, encompassing 11 generations with several hundred of affected subjects, was achieved through the meticulous study of medical records in the archives of the Provincial Psychiatric Hospital of Girifalco in Italy and in the municipal and parish archives of many towns belonging to the same geographical area. The research on N family triggered several other studies on hereditary neurodegenerative disorders in Southern Italy. Investigation focusing on antique archives and the analysis of phenotypes allowed to reconstruct and clinically detail large pedigrees of hereditary diseases, such as frontotemporal dementia and spinocerebellar ataxia 17, even before the discovery of their causative genes.
 


Numerous studies predict that the number of older adults who have cognitive impairment associated with impairments in the realisation of activities of daily living, namely people with dementia, will triple by 20501 and that this increase will submerge families and healthcare systems, as well as impose an unbearable economic burden on society. In order to prevent this so-called “social crisis of dementia”, the dominant biomedical position considers that we should strive to find the neurobiological causes of dementia, develop neurobiological procedures to diagnose it as early as possible, and identify pharmacological treatments to delay its onset and, ultimately, to cure it.

From this position and in line with these objectives, significant changes in clinical practice have been implemented since the early 1990s2. First, an increasing number of memory clinics have been established in order to identify people with a dementing disease, or with a pre-dementia state, and to provide them with (so far non-effective) pharmacological treatments. Second, diagnostic categories such as Mild Cognitive Impairment (MCI3) were created to account for the cognitive difficulties, formerly considered to be benign and related to ageing, that some elderly people experience as they grow older. Finally, new diagnostic procedures based on biological markers were developed in order to identify the presence of dementia as early as possible (i.e., even before it is expressed through cognitive deficits).

Altogether, these changes in clinical practice indicate that the reductionist biomedical approach to dementia has strengthened throughout the last 30 years and that, consequently, medicalisation, pathologisation, and stigmatisation of cerebral and cognitive ageing have increased.

According to the dominant biomedical position, Alzheimer’s disease (AD) is a chronic and progressive disease that can be identified on the basis of specific cognitive symptoms (in particular, episodic memory deficits) and neuropathological characteristics (i. e., neurotic plaques and neurofibrillary tangles)4. Importantly, this approach considers AD to be intrinsically different from normal ageing and other neurodegenerative diseases and proposes that, by pursuing extensive research on what are considered the specific neuropathological characteristics of AD, we will eventually be able to identify the cause of this disease and develop medical treatments that will allow us to successfully cure it.

However, throughout the last two decades, different types of evidence led a growing number of scientists to question and criticise the foundations of this essentialist and category-based approach5-8 (see Van der Linden9 for a complete review). In particular, several studies have highlighted that AD can express itself through different cognitive deficits. For instance, using latent class analysis, Scheltens and colleagues10 have identified eight distinct cognitive profiles in a large sample of patients diagnosed with AD. Amongst these profiles, only two were characterised by predominant memory impairments, while the other six described a mixture of language, attentional, executive, and/or visuospatial difficulties without memory impairments. Importantly, all of these profiles were associated with different demographical and neurobiological characteristics. Taken together, these results suggest that AD does not have any diagnostic specificity at the cognitive and biological levels and further imply that the current biomedical conceptualisation of AD cannot account for the complexity and heterogeneity of this condition.

In the same vein, numerous studies have demonstrated that the evolution of cognitive and functional difficulties can greatly vary amongst people diagnosed with AD. For instance, Tschanz and colleagues11 have shown that the deterioration rate of older adults with dementia commonly differs from one person to another and that, for a significant proportion of people with this condition, the progression of their cognitive, behavioural, and functional difficulties is slow, or even null, throughout their last years of life. Furthermore, other studies12 have found that spontaneous improvement can be seen in both brain structure and cognitive function amongst some older adults who were diagnosed with AD and cases of “reversible” AD have also been described13. Importantly, all of these studies suggest that age-related brain modifications are the results of a dynamic process that involves many risk and protective factors.

In this context, it is also worth noting that many authors have criticised the use of MCI in clinical practice because of the low validity of this diagnosis14. Specifically, Klekociuk and colleagues15 have pointed out that the criteria for MCI have not been clearly operationalised and have also emphasised that MCI is longitudinally unstable, with many people who bear this diagnosis remaining stable or “recovering” to age-appropriate levels of functioning later in their life.

Finally, at the cerebral level, it is now well recognised that co-occurrence of multiple pathologies (e.g., various extra- and intra-cellular abnormal protein deposits, cerebrovascular disorders, hippocampal sclerosis, etc.) is frequent in the brains of both cognitively intact and cognitively impaired older adults16-18. Importantly, this finding implies that it is impossible to define a clear boundary between normal and abnormal ageing at the cerebral level.

Altogether, these findings have lead a growing number of authors to suggest that we must free ourselves from the reductionist biomedical conceptualisation of AD and that, instead of imprisoning people in pathologising and stigmatising diagnostic categories, we should reinstate the different expressions of this supposedly specific disease in a broader framework of cerebral and cognitive ageing (see Van der Linden19 for a detailed presentation of this perspective).

Explicitly, according to this alternative and more recent perspective, the nature and extent of the cognitive and functional difficulties that people experience as they grow older are modulated by a myriad of factors and mechanisms that interact throughout the lifespan20-22. In particular, numerous epidemiological studies have shown that the factors that influence cognitive and cerebral ageing are biological (e.g., age, cardiovascular risk factors, diabetes, etc.), psychological (e.g., depression, anxiety, stress, etc.), environmental (e.g., environmental toxins, etc.), social (e.g., social isolation, etc.), cultural (e.g., living in a society that holds negative stereotypes towards ageing), and related to one’s lifestyle (e.g., lack of regular physical activity, etc.) in nature23. Importantly, these factors are thought to operate through a complex set of interacting mechanisms24 and to function either as risk or as protective factors depending on how each person relates to them individually.

To date, only a few authors have tried to adopt an ageing perspective in view of understanding how the mechanisms that are implicated in the development of cognitive and functional difficulties in late life operate. One notable contribution to this line of thought is Herrup’s theory25, which proposes that there are three key steps to the development of AD: (1) an initiating brain damage that can be related to various types of problems (e.g., physical traumas, vascular problems, stress associated with a major life event, etc.), (2) a prolonged neuroinflammatory response, and (3) a discontinuous cellular change-of-state involving most types of brain cells. Explicitly, Herrup explains that advancing age leads to a higher frequency of brain damage and that, because getting older naturally diminishes the structural complexity of brain cells and weakens the brain’s defences, any form of brain damage that occurs in old age will lead to a prolonged neuroinflammatory response in an attempt to correct the damage. According to this theory, it is the prolonged nature of this neuroinflammatory response that generates the different neurobiological phenomena that can lead to AD (i.e., amyloid deposition cycle, attempts at cell cycle re-entry, synaptic dysfunction, and, ultimately, neuronal death). Importantly, Herrup considers that different types of initiating damage can co-exist and that each type of damage will generate different responses from brain cells, which will in turn lead to different types of problematic manifestations.

Adopting a perspective that takes into account the variability and complexity of cerebral and cognitive ageing calls for a shift in terms of research objectives and leads to envisaging significant changes with regards to neuropsychological assessment and intervention in clinical practice26 (see Van der Linden19 for a more detailed presentation). Explicitly, in terms of research, it now seems essential that more studies be conducted from a perspective that considers cerebral and cognitive ageing as a continuum rather than on a categorical basis27. In addition, rather than solely focusing on small molecules, researchers should adopt an integrative and systemic perspective24 and aim to examine how various combinations of adverse and compensatory neurobiological mechanisms contribute to the development of the different phenotypes and neuropathological expressions observed in dementia28.

In terms of assessment practices, taking into consideration the heterogeneity and multifactorial character of the cognitive, behavioural, and socio-emotional manifestations of the so-called neurodegenerative diseases renders irrelevant the use of neuropsychological assessments for differential diagnosis, or for predicting the evolution of cognitive difficulties. Instead, we believe that the objectives of a neuropsychological assessment should remain to identify the emergence of cognitive, behavioural, socio-emotional, and functional difficulties in the elderly, to understand the nature of these difficulties, and to monitor their evolution. Importantly, we also argue that clinical neuropsychologists should (a) explore how the person (and his or her family/carers) experiences his or her difficulties, (b) identify risk factors that could be the object of preventive measures, and (c) aim to understand the nature of the person’s problems in everyday life, so as to more efficiently optimise the quality of life and well-being of older adults by means of individualised psychological and social interventions. More generally, we think that clinicians should conduct their neuropsychological assessment with the aim of formulating an individualised and comprehensive case formulation29.

Finally, with regards to intervention practices, due to the heterogeneity and complexity of cerebral and cognitive ageing, it seems unlikely that any “ready-made” intervention program will be able to meet all of the different needs of elderly adults who experience cognitive and/or functional difficulties. In particular, research has shown that, to date, there exists no pharmacological intervention that has been shown to have a real positive effect on the autonomy and quality of life of people diagnosed with this condition30. In order to promote older people’s wellbeing and autonomy, we therefore suggest that clinicians should adopt an individualised and multifaceted approach in their practice, and that they should target specific goals (established with the person and with her relatives) that can have a concrete impact on people’s daily life (see Clare31 and Jha32 for illustrations of this principle). Furthermore, in view of the variety of factors that can influence cerebral and cognitive ageing throughout the lifespan, we also believe that preventive measures have a significant role to play in terms of future interventions. In support of this claim, Barnes and Yaffe33 have recently estimated that the reduction of seven risk factors (i.e., depression, smoking, diabetes, hypertension in midlife, obesity in midlife, low education level or cognitive inactivity and lack of physical activity) would lead to a significant decrease in the number of AD cases worldwide. Importantly, the results of this study imply that we could significantly change ageing trajectories by implementing a series of preventive measures on a societal level (e.g., early detection and management of cardio-vascular diseases and diabetes, encouraging people to exercise regularly and to maintain a socially and cognitively active life throughout their midlife and old age, etc.), but they do not intend to convey the message that people should be held responsible for their cognitive and functional difficulties if they experience some in later life34.

In light of this short review, we would like to conclude by emphasising that adopting this lifespan and plurifactorial perspective on AD and dementia invites us to think differently about ageing. In particular, it leads us to consider the world as a place in which we all share vulnerabilities of cerebral and cognitive ageing and, instead of simply separating those who present cognitive and functional difficulties from those who do not by means of a diagnosis, it encourages us to create more unity between generations.

Funding: The authors received no financial support for the research, authorship, and/or publication of this article.

Declaration of competing interests: The authors report no competing interests with respect to the research, authorship, and/or publication of this article.

  1. World Health Organization. Dementia (Fact Sheet N°362). (April 2016). Available from: http://www.who.int/mediacentre/factsheets/fs362/en/
  2. Le Couteur DG, Doust J, Creasey H, et al. Political drive to screen for pre-dementia Not evidence-based and ignores the harms of diagnosis. BMJ. 2013; 347: 1-6.
  3. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011; 7(3): 270-279.
  4. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011; 7(3): 263-269.
  5. de la Torre JC. A turning point for Alzheimer’s disease. Biofactors. 2012; 28(2): 78-83.
  6. Richard E, Schmand B, Eikelenboom P, et al. The Alzheimer myth and biomarker research in dementia. J Alzheimers Dis. 2012; 31: S203-S209.
  7. Brayne C, Davis D. Making Alzheimer’s and dementia research fit for populations. Lancet. 2013; 380(9851): 1441-1443.
  8. Castellani RJ, Perry G. Pathogenesis and disease modifying therapy in Alzheimer’s disease The flat line of progress. Arch Med Res. 2012; 43(8): 694-698.
  9. Van der Linden M, Juillerat Van der Linden AC. Penser autrement le vieillissement Thinking ageing differently. Brussels, Belgium: Mardaga; 2014.
  10. Scheltens AME, Galindo Garre F, Pijnenburg YA, et al. The identification of cognitive subtypes in Alzheimer’s disease dementia using latent class analysis. J Neurol Neurosurg Psychiatry. 2016; 87: 235-243.
  11. Tschanz JT, Corcoran CD, Schwartz S, et al. Progression of cognitive functional and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia. Am J Geriatr Psychiatry. 2011; 19(6): 532-542.
  12. Song X, Mitnitski A, Zhang N, et al, for the Alzheimer’s Disease Neuroimaging Initiative. Dynamics of brain structure and cognitive function in the Alzheimer’s disease neuroimaging initiative. J Neurol Neurosurg Psychiatry. 2013; 84(1): 71-78.
  13. Fisher P, Jungwirth S, Hinterberger M, et al. “Reversible” Alzheimer’s disease. J Am Geriatr Soc. 2011; 59(6): 1137-1138.
  14. Stephan BCM, Kurth T, Matthews FE, et al. Dementia risk prediction in the population: Are screening models accurate. Nat Rev Neurol. 2010; 6(6): 318-326.
  15. Klekociuk SZ, Saunders NL, Summers MJ. Diagnosing mild cognitive impairment as a precursor to dementia: Fact or fallacy. Aust Psychol. 2016; 51(5), 366-373.
  16. Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006; 66(12):1837-1844.
  17. Elobeid A, Rantakömi S, Soininen H, et al. Alzheimer’s disease-related plaques in nondemented subjects. Alzheimers Dement. 2014; 10(5): 522-529.
  18. Jellinger KA, Attems J. Challenge of multimorbidity of the aging brain: A critical update. J Neural Transm. 2015: 122(4), 505-521.
  19. Van der Linden M, Juillerat Van der Linden AC. A life-course and multifactorial approach to Alzheimer’s disease: Implications for research clinical assessment and intervention practices. Dementia. 2016; 0(0): 1-16.
  20. Whalley LJ, Dick FD, McNeill G. A life course approach to the aetiology of late-onset dementias. Lancet Neurol. 2006; 5(1): 87-96.
  21. Fotuhi M, Hachinski V, Whitehouse PJ. Changing perspectives in late-life dementia. Nat Rev Neurol. 2009; 5(12): 649-658.
  22. Chen M, Maleski J, Sawmiller DR. Scientific truth or false hope Understanding Alzheimer’s disease from an aging perspective. J Alzheimers Dis. 2011; 24(1): 3-10.
  23. Blazer DG, Yaffe K, Liverman CT. Cognitive aging Process in understanding and opportunities for action. Washington, DC: The National Academies Press; 2015.
  24. Kling MA, Trojanowski JQ, Wolk DA, et al. Vascular disease and dementias: Paradigm shifts to drive research in new directions. Alzheimers Dement. 2013; 9(1): 76-92.
  25. Herrup K. Re-imagining Alzheimer’s disease An age-based hypothesis. J Neurosci. 2010; 30(50): 16755-16762.
  26. Van der Linden M, Juillerat Van der Linden AC. L’évaluation neuropsychologique dans la démence un changement d’approche [Neuropsychological assessment in dementia: changing the current approach]. In: Seron X, Van der Linden M, editors. Traité de neuropsychologie clinique de l’adulte, 2e édition, Tome 1 [Treaty of adult clinical neuropsychology, 2nd edition, Book 1]. Bruxelles, Belgium: De Boeck/Solal; 2014. p. 575-599.
  27. Walhovd KB, Fjell AM, Epseseth T. Cognitive decline and brain pathology in agingmNeed for a dimensional, lifespan and systems vulnerability view. Scand J Psychol. 2014; 55(3): 244-254.
  28. Reuter Lorenz PA, Park DC. How does it STAC up Revisiting the scaffolding theory of aging and cognition. Neuropsychol Rev. 2014; 24(3): 355-370.
  29. Kinderman P. A psychological model of mental disorder. Harv Rev Psychiatry. 2005; 13(4): 206-217.
  30. Cooper C, Mukadam N, Katona C, et al. Systematic review of effectiveness of pharmacological interventions to improve quality of life and well-being of people with dementia. Am J Geriatr Psychiatry. 2013; 21(2): 173-183.
  31. Clare L, Linden DE, Woods RT, et al. Goal-oriented cognitive rehabilitation for people with early-stage Alzheimer’s disease: A single blind randomized controlled trial of efficacy. Am J Geriatr Psychiatry. 2010; 18(10): 928-939.
  32. Jha A, Jan F, Gale T, et al. Effectiveness of a recovery-oriented psychiatric intervention package on the wellbeing of people with early dementia: A preliminary randomised controlled trial. Int J Geriatric Psychiatry. 2013; 28(6): 589-596.
  33. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 2011; 10(9): 819-828.
  34. Katz S, Calasanti, T. Critical perspectives on successful aging: Does it “appeal more than illuminates”. Gerontologist. 2015; 55(1): 26-33.
 
 

Article Info

Article Notes

  • Published on: May 15, 2017

Keywords

  • neurodegenerative diseases
  • Alzheimer's disease

*Correspondence:

Dr. Amalia Cecilia Bruni,
Centro Regionale di Neurogenetica, Azienda Sanitaria Provinciale Catanzaro,
Viale A. Perugini, 88046 Lamezia Terme (CZ), Italy, Tel.: +39-0968 208080,
Fax: +39-0968 208032, 
Email: amaliaceciliabruni@gmail.com
© 2017 Bruni CA. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License